| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
VD2-D3 targets the vitamin D receptor (VDR), a nuclear receptor that mediates the biological actions of vitamin D and its metabolites. Upon binding to VDR, the ligand-receptor complex heterodimerizes with the retinoid X receptor (RXR) and binds to vitamin D response elements (VDREs) in the promoter regions of target genes, regulating the expression of genes involved in calcium homeostasis, bone metabolism, immune function, and cell differentiation. The deuterated D3 form of Vitamin D2 serves as an analytical internal standard for quantifying Vitamin D2 levels in biological matrices and does not alter the receptor binding or transcriptional activity compared to the parent compound.
|
|---|---|
| ln Vitro |
In vitro, VD2-D3 is used as an internal standard for the quantification of Vitamin D2 in biological samples by LC-MS/MS. The deuterated analog exhibits nearly identical physicochemical properties to the parent compound, including similar lipophilicity, protein binding, and receptor binding affinity, making it suitable as an internal standard. Vitamin D2 (ergocalciferol) itself is a form of vitamin D that is converted in the liver to 25-hydroxyvitamin D2 and then in the kidney to the active form 1,25-dihydroxyvitamin D2, which binds to VDR and regulates gene expression. The D3-labeled form enables accurate quantification of Vitamin D2 and its metabolites in pharmacokinetic and clinical studies.
|
| ln Vivo |
In vivo, VD2-D3 is used as an internal standard for pharmacokinetic studies and therapeutic drug monitoring of Vitamin D2. Vitamin D2 is obtained from dietary sources and supplements and is metabolized in the liver to 25-hydroxyvitamin D2, the major circulating form, and subsequently to the active hormone 1,25-dihydroxyvitamin D2 in the kidney. The deuterated D3 analog enables accurate quantification of Vitamin D2 and its metabolites in plasma, serum, and tissue samples by LC-MS/MS. This allows researchers to study vitamin D metabolism, bioavailability, and the effects of vitamin D supplementation in clinical and preclinical studies.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for vitamin D metabolites involve measuring the binding affinity of Vitamin D2 or its metabolites to the vitamin D receptor (VDR). Recombinant VDR protein is incubated with radiolabeled [3H]-1,25-dihydroxyvitamin D3 or a fluorescently labeled VDR ligand in assay buffer. Varying concentrations of unlabeled Vitamin D2 or its metabolites are added to compete for binding. After incubation at 4degC for 2-24 hours, bound and free ligand are separated by charcoal-dextran precipitation or hydroxylapatite adsorption. Bound radioactivity is quantified by liquid scintillation counting. Ki values are calculated using the Cheng-Prusoff equation. The D3 internal standard is used in LC-MS/MS quantification rather than in binding assays.
|
| Cell Assay |
Cellular assays for vitamin D compounds are performed using cell lines expressing VDR, such as osteosarcoma cells (MG-63, SaOS-2), intestinal epithelial cells (Caco-2), or immune cells (macrophages). Cells are cultured in appropriate medium and seeded in 6- or 96-well plates. Cells are treated with Vitamin D2 or its metabolites (0.001-100 nM) for 24-72 hours. VDR-mediated transcriptional activity is assessed using a luciferase reporter assay with a VDRE-containing promoter. Gene expression of VDR target genes (e.g., CYP24A1, osteocalcin, TRPV6) is quantified by qRT-PCR. Cell proliferation and differentiation are assessed by MTT assay and alkaline phosphatase activity. The D3 internal standard is used in LC-MS/MS quantification of Vitamin D2 in cell lysates.
|
| Animal Protocol |
In vivo animal studies for Vitamin D2 are conducted in rodent models to study vitamin D metabolism and bone health. Rats or mice are administered Vitamin D2 orally or intraperitoneally at doses of 0.1-10 microg/kg. Blood samples are collected at various time points for measurement of Vitamin D2 and its metabolites (25-hydroxyvitamin D2, 1,25-dihydroxyvitamin D2) by LC-MS/MS using the D3 internal standard. Bone mineral density is measured by DXA or micro-CT. Calcium and phosphorus levels in serum and urine are measured. Histological analysis of bone and other tissues is performed. Pharmacokinetic parameters (Cmax, Tmax, AUC, t1/2) are calculated.
|
| ADME/Pharmacokinetics |
VD2-D3 (CAS#: 1217448-46-8) has molecular formula C2₈H41D3O and molecular weight 399.67. The compound is a deuterium-labeled form of Vitamin D2 (ergocalciferol) with three deuterium atoms at positions 6, 19, and 19. It is an isotopically labeled compound used as an internal standard for the quantification of Vitamin D2 in biological samples by LC-MS/MS. The compound is a solid and should be stored at -20degC, protected from light. It is soluble in organic solvents such as ethanol, methanol, and DMSO. The compound is intended for research use only and is not for human therapeutic applications.
|
| Toxicity/Toxicokinetics |
Toxicological information for VD2-D3 is primarily extrapolated from Vitamin D2. Vitamin D is generally safe at recommended doses, but excessive intake can cause hypercalcemia, hypercalciuria, and soft tissue calcification. Symptoms of vitamin D toxicity include nausea, vomiting, weakness, confusion, and kidney stones. The deuterated D3 form is intended for research use as an analytical standard and is not for human therapeutic use. Standard laboratory precautions should be observed when handling the compound, including the use of personal protective equipment. The compound should be stored at -20degC, protected from light and moisture.
|
| Additional Infomation |
VD2-D3 (CAS#: 1217448-46-8), also known as Vitamin D2 (Ergocalciferol) (6,19,19-D3), is a deuterium-labeled internal standard for Vitamin D2. Vitamin D2 (ergocalciferol) is a form of vitamin D obtained from dietary sources and supplements. It is metabolized in the liver to 25-hydroxyvitamin D2 and in the kidney to the active hormone 1,25-dihydroxyvitamin D2, which binds to the vitamin D receptor (VDR) and regulates calcium homeostasis, bone metabolism, and immune function. The D3-labeled analog is used in LC-MS/MS bioanalytical methods for vitamin D quantification in clinical and research settings. For research use only, not for human therapeutic applications.
|
| Molecular Formula |
C28H44O
|
|---|---|
| Molecular Weight |
396.64836
|
| Exact Mass |
399.358
|
| CAS # |
1217448-46-8
|
| PubChem CID |
66577029
|
| Appearance |
White to off-white solid powder
|
| Flash Point |
14 °C
|
| LogP |
7.641
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
29
|
| Complexity |
678
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
[2H]C(=C\1CC[C@@H](C/C1=C(\[2H])/C=C/2\CCC[C@]3([C@H]2CC[C@@H]3[C@H](C)/C=C/[C@H](C)C(C)C)C)O)[2H]
|
| InChi Key |
MECHNRXZTMCUDQ-OQGZBSKRSA-N
|
| InChi Code |
InChI=1S/C28H44O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-20,22,25-27,29H,4,7-8,11,14-18H2,1-3,5-6H3/b10-9+,23-12+,24-13-/t20-,22+,25-,26+,27-,28+/m0/s1/i4D2,13D
|
| Chemical Name |
(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]-1-deuterioethylidene]-4-(dideuteriomethylidene)cyclohexan-1-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~250.21 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5211 mL | 12.6056 mL | 25.2111 mL | |
| 5 mM | 0.5042 mL | 2.5211 mL | 5.0422 mL | |
| 10 mM | 0.2521 mL | 1.2606 mL | 2.5211 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
